期刊文献+

circDLGAP4及miR-34c在帕金森病患者血清中的表达及临床意义

Expression and Clinical Significance of circDLGAP4 and miR-34c in the Serum of Patients with Parkinson′s Disease
下载PDF
导出
摘要 目的:探讨环状RNA-DLGAP4(circular RNA-DLGAP4,circDLGAP4)及微小RNA-34c(microRNA-34c,miR-34c)在帕金森病(Parkinson′s disease,PD)患者血清中的表达及其对疾病的诊断价值。方法:选取2019年1月至2021年1月我院收治的72例PD患者作为PD组,并根据Hoehn-Yahr分级对PD患者进行分组。另选取同期在我院体检的健康志愿者75例作为对照组。通过实时荧光定量PCR检测两组受试者血清circDLGAP4及miR-34c的相对表达量,并通过统一帕金森病评定量表(UPDRS)统计PD患者UPDRSⅠ、UPDRSⅡ及UPDRSⅢ评分。通过Pearson相关性、受试者工作特征(ROC)曲线分析circDLGAP4及miR-34c在PD中的诊断价值。结果:PD组患者血清circDLGAP4和miR-34c表达水平低于对照组(P<0.05)。中度组PD患者血清circDLGAP4和miR-34c表达水平较轻度组更低(P<0.05);重度组PD患者血清circDLGAP4和miR-34c表达水平较中度组更低(P<0.05)。PD患者血清circDLGAP4和miR-34c表达水平与UPDRSⅡ评分、UPDRSⅢ评分、Hoehn-Yahr分级呈负相关(P<0.05)。血清circDLGAP4、miR-34c联合检测对PD的诊断效能更高。结论:circDLGAP4及miR-34c可作为诊断PD的分子标志物。 Objective:To investigate the expression and diagnostic value of circDLGAP4 and miR-34c in the serum of Parkinson′s disease(PD)patients.Methods:72 PD patients admitted to our hospital from January 2019 to January 2021 were selected as the PD group,and were grouped according to Hoehn-Yahr grade.In addition,75 healthy volunteers who underwent physical examination in our hospital during the same period were selected as the control group.The relative expression levels of circDLGAP4 and miR-34c in the serum of the two groups of subjects were detected by real-time quantitative PCR,and the UPDRSⅠ,UPDRSⅡand UPDRSⅢscores of PD patients were calculated by the Unified Parkinson′s Disease Rating Scale(UPDRS).The diagnostic value of circDLGAP4 and miR-34c in PD was analyzed by the method of Person correlation and receiver operating characteristic(ROC)curve.Results:The serum circDLGAP4 and miR-34c expression levels in the PD group were lower than those in the control group(P<0.05).The serum circDLGAP4 and miR-34c expression levels in moderate group Parkinson′s disease patients were lower than those in the mild group(P<0.05).The serum circDLGAP4 and miR-34c expression levels in severe group Parkinson′s disease patients were lower than those in the moderate group(P<0.05).The serum circDLGAP4 and miR-34c expression levels in PD patients were negatively correlated with UPDRSⅡscore,UPDRSⅢscore and Hoehn-Yahr grade(P<0.05).The combined detection of serum circDLGAP4 and miR-34c is more valuable in the diagnosis of PD.Conclusion:circDLGAP4 and miR-34c can be used as the molecular markers to diagnose PD.
作者 翟海燕 杨杰 ZHAI Haiyan;YANG Jie(Department of Neurology,No.215 Hospital of Shaanxi Nuclear Industry,Shaanxi Xianyang 712000,China)
出处 《中国医药导刊》 2023年第3期281-285,共5页 Chinese Journal of Medicinal Guide
基金 陕西省重点研发计划(项目编号:2018SF-143,项目名称:脑脊液外泌体miR-19b在帕金森病小鼠脑脊液表达及调控神经炎症作用机制研究)。
关键词 帕金森病 circDLGAP4 miR-34c 血清 诊断价值 生物标志物 Parkinson′s disease circDLGAP4 miR-34c Serum Diagnostic value Biomarkers
  • 相关文献

参考文献5

二级参考文献49

  • 1张振馨.帕金森病的诊断[J].中华神经科杂志,2006,39(6):408-409. 被引量:616
  • 2Clarke CE, Patel S, Ives N, et al. Should treatment for Parkinson' s disease start immediately on diagnosis or delayed until functional disability develops? [ J 1. Mov Disord, 2011, 26 (7) : 1187-1193.
  • 3Breen DP, Evans JR, Farrell K, et al. Determinants of delayed diagnosis in Parkinson' s disease[ J]. J Neurol, 2013, 260 (8) : 1978-1981.
  • 4Maetzler W, Liepeh I, Berg D. Progression of Parkinson' s disease in the clinical phase: potential markers [ J ]. Lancet Neurol, 2009, 8(12) : 1158-1171.
  • 5Gaenslen A, Swid I, Liepelt-Scarfone I, et al. The patients' perception of prodromal symptoms before the initial diagnosis of Pm'kinson' s disease[Jl. Mov Disord, 2011, 26(4): 653-658.
  • 6Gaeslen A, Wurster I, Brockmann K, et al. Prodromal features for Parkinson' s disease-baseline data from the TREND study[ J]. Eur J Neurol, 2014, 21(5): 766-772.
  • 7O' Sullivan SS, Williams DR, Gallagher DA, et al. Nonmotor sympoms as presenting complaints in Parkinson' s disease: a clinicopathological study[J]. Mov Disord, 2008, 23( 1 ): 101- 106.
  • 8Zhang ZX, Roman GC, Hong Z,et al. Parkinson's disease inChina: prevalence in Beijing, Xian, and Shanghai[ J]. Lancet,2005,365(9459): 595-597.
  • 9Postuma RB, Berg D, Stem M, et al. MDS clinical diagnosticcriteria for Parkinson、disease[ J]. Mov Disord, 2015,30( 12):1591-1601. DOI: 10.1002/mds.26424.
  • 10Chaudhuri KR, Healy DG, Schapira AH, et al. Non-motorsymptoms of Parkinson's disease : diagnosis and management[ J ].Lancet Neurol, 2006,5(3): 235-245.

共引文献1224

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部